PLUS THERAPEUTICS, INC. Segments Disclosure
17. Segment Information
The Company operates under one reportable business segment to advance the development, manufacturing and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The determination of a single reportable business segment is consistent with the consolidated financial information regularly provided to the Company’s CODM. All of the Company's long-term assets and operations are located in the United States. The Company’s CODM is its , who reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and financial performance, including comparing actual results to budgets and forecasts to assess variances, identify trends, and guide strategic planning.
In addition to the significant expense categories included within the consolidated statements of operations, the below disaggregated amounts comprise significant research and development and general and administrative expenses. These expenses consist of (1) clinical, manufacturing and research contracts for research and development programs, (2) personnel-related expenses, including salaries, benefits and share-based compensation, (3) professional fees, including third-party costs for goods and services such as lab supplies and contract research, and legal and other professional expenses, and (4) facility and other overhead expenses, including depreciation, occupancy, travel, insurance and other costs.
|
|
Year Ended December 31 |
|
|||||
(in thousands) |
|
2025 |
|
|
2024 |
|
||
Research and development |
|
|
|
|
|
|
||
Clinical, development and licensing expenses |
|
$ |
3,898 |
|
|
$ |
4,549 |
|
Personnel related expenses |
|
|
2,103 |
|
|
|
3,026 |
|
Professional fees |
|
|
1,224 |
|
|
|
1,733 |
|
Facility and other overhead expenses |
|
|
1,154 |
|
|
|
1,272 |
|
Total research and development |
|
|
8,379 |
|
|
|
10,580 |
|
General and administrative |
|
|
|
|
|
|
||
Personnel related expenses |
|
|
5,611 |
|
|
|
3,454 |
|
Professional expenses |
|
|
4,970 |
|
|
|
4,828 |
|
Facility and other overhead expenses |
|
|
1,551 |
|
|
|
1,657 |
|
Total general and administrative |
|
$ |
12,132 |
|
|
$ |
9,939 |
|
All of the Company's long-term assets and operations are located in the United States.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 12, 2026 | Showing above |
| 2024 | Mar 31, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.